Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
about
Molecular biology of lung cancerMolecular testing in lung cancer in the era of precision medicineALK and ROS1 as a joint target for the treatment of lung cancer: a reviewReview of the current targeted therapies for non-small-cell lung cancerTargeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastomaStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Activation of RAS family members confers resistance to ROS1 targeting drugs.Nivolumab in NSCLC: latest evidence and clinical potentialRedundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCRActivated RET and ROS: two new driver mutations in lung adenocarcinoma.The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.Lack of ROS1 Gene Rearrangement in Glioblastoma MultiformeClinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis.Personalizing therapy in advanced non-small cell lung cancerROS1 copy number alterations are frequent in non-small cell lung cancer.Novel targets in non-small cell lung cancer: ROS1 and RET fusionsRare Incidence of ROS1 Rearrangement in Cholangiocarcinoma.Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.Protein kinase inhibitors to treat non-small-cell lung cancer.Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.Management of NSCLC: focus on crizotinib.MET inhibition in lung cancer.Chromosomal Rearrangements in Cancer: Detection and potential causal mechanisms.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Histopathologic diagnosis of brain metastases: current trends in management and future considerations.Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.Nicotinamide N-methyltransferase in non-small cell lung cancer: promising results for targeted anti-cancer therapy.Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma.Crizotinib targets in glioblastoma stem cells.Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.The role of osmolarity adjusting agents in the regulation of encapsulated cell behavior to provide a safer and more predictable delivery of therapeutics.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology.ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.[Clinical significance of ROS1 rearrangements in non-small cell lung cancer].Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.
P2860
Q24606677-9641A758-B37E-4622-9EAB-6D998BD2B912Q26824599-7BE11B1E-680B-4529-8929-CDA2494EA87FQ26851392-A35C5B0B-DA86-4C08-9281-EA3238BE58AEQ27015079-4EE5FFB5-D3BD-4C70-B66C-D52064D3366EQ27022941-B8EFED81-5D88-45EB-A0ED-65D96BB8FD0DQ27853214-A92E8446-7809-4954-B932-9E50F8A4FBB5Q34463388-7FED8CE7-CF62-4D69-9BF9-9EBDB1F10EAAQ34466452-FA8E53D0-5AA1-4C0A-BB1D-BAB3F1F9E5F5Q34704781-3C00F23C-9F04-46E5-9376-A4682CDF7377Q34871953-5DE8C358-E6EC-45A7-86C0-636E6A1440B5Q35151926-DD572FD4-B934-4F88-86EA-206DD504401FQ35206630-58BE1ECF-9D8A-4E82-8A6E-047FC3D19686Q35532823-5C73713E-85FA-4D95-A993-13F4C9903C0DQ35772397-C63F6D73-B5C3-4AC9-A602-5E8D65289A52Q35790161-39CE6592-3DDD-49E4-A5CB-A7AC7BE71B79Q36811453-71CA729E-CFF9-4595-A10A-9ED886944244Q36946705-C8E08CC0-6033-44B5-96E5-5FCF69B460B3Q37038500-60D190DF-0CE6-4225-9463-5439026E9357Q37606680-F2D9BD48-E81C-462B-BCB8-51C6C8AB54B2Q37711636-1FB35DAB-266E-4EFE-8B67-45B30E912A2AQ38205518-6C70577D-CFC0-4BBD-9913-5A89C6388E56Q38213830-64A071F4-6C7C-44FA-959B-E7E4FC18DA6FQ38258633-B6EE5470-A3C0-48A8-9CD4-AFE29AFD676DQ38390016-8FEE35FE-CA19-46D0-B61C-8D40B8DF9134Q38552583-91EBEB93-E8A1-4D4E-8B60-A0B7BE644AACQ38653663-26AD01C5-DC55-4C69-8881-4BFDDD6D8ED8Q38791747-6E410E20-75AA-4B88-A0CA-E40771E8ACDAQ39126870-70829054-0577-4A32-8CD0-AB9A68C6BC71Q44201011-CE1A9927-589F-4F27-8EE0-117E561EF6D2Q47094941-6D63F19B-EFFC-427E-85BA-33BBD9E4DB29Q47122191-25A070AA-09E2-4A7F-832D-3A59885BBBDCQ47139758-6530111A-8EFE-4BA9-B3A0-40DC3AB05800Q47351169-181B6AAB-B7F1-40D3-A50A-3A7A149ECF1DQ47701441-DCF4ECB4-4192-4F75-8AF0-9B7C364CC11DQ48179589-A5995042-728D-4EE1-9326-8351DB4A36C0Q48263612-049DA239-48EC-4318-A515-7E416E50A19DQ48536576-34462D5A-7F37-4793-BAC2-5239BDE7A43AQ51166232-11715029-F478-47B5-8A9D-623A09B925D0Q54389938-64B10068-FEC0-4C3E-A70A-BFDC28E48162Q54978820-94957340-26D7-4607-BE97-5DF056498BD2
P2860
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting ROS1 with anaplastic ...... of non-small-cell lung cancer.
@en
type
label
Targeting ROS1 with anaplastic ...... of non-small-cell lung cancer.
@en
prefLabel
Targeting ROS1 with anaplastic ...... of non-small-cell lung cancer.
@en
P2093
P1476
Targeting ROS1 with anaplastic ...... of non-small-cell lung cancer
@en
P2093
Leow Pay Chin
Ross A Soo
Sai-Hong I Ou
P304
P356
10.1097/JTO.0B013E31826BAF83
P50
P577
2012-11-01T00:00:00Z